[The role of sulphonylurea derivatives in treatment of diabetes type 2. The role of glimepiride].
Type 2 diabetes is characterised by some kind of duality. In its pathogenesis an important role have as well genetic as environmental factors. Both of them influence the insulin secretion at the one side and the insulin resistance at the other one. Very important group of antidiabetic drugs are sulphonylureas. They bind to the sulphonylurea receptor localized at the potassium channel in the cellular membrane. Contemporary sulphonylurea derivatives should be characterised by rather weak binding with the receptor, action during mealtime only (prandial regulation of glycemia), not to strong insulin secretion and for the quality of life reason once daily application. This criteria are fulfilled by e.g. slow-releasing preparations of glipizide and glikiazide and also by glimepiride.
Sieradzki
J
J
Katedra i Klinika Chorób Metabolicznych Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie.
D018528:ATP-Binding Cassette Transporters; D003692:Delayed-Action Preparations; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000097:blood; D010455:Peptides / Q000097:blood; D015221:Potassium Channels / Q000378:metabolism; D024661:Potassium Channels, Inwardly Rectifying; D011955:Receptors, Drug / Q000378:metabolism; D013453:Sulfonylurea Compounds / Q000008:administration & dosage* / Q000378:metabolism; D064233:Sulfonylurea Receptors
D018528:ATP-Binding Cassette Transporters; D003692:Delayed-Action Preparations; D007328:Insulin; D010455:Peptides; D015221:Potassium Channels; D024661:Potassium Channels, Inwardly Rectifying; D011955:Receptors, Drug; D013453:Sulfonylurea Compounds; D064233:Sulfonylurea Receptors; C050632:polypeptide C